Johnson & Johnson (NYSE:JNJ) Shares Bought by Chapin Davis Inc.

Chapin Davis Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 24.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,935 shares of the company's stock after purchasing an additional 5,680 shares during the period. Johnson & Johnson comprises 1.6% of Chapin Davis Inc.'s holdings, making the stock its 14th largest position. Chapin Davis Inc.'s holdings in Johnson & Johnson were worth $4,799,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the 4th quarter worth about $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson in the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter worth about $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on JNJ shares. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Finally, The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $152.27 on Wednesday. The firm has a market cap of $366.36 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 2.29 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The business's 50 day moving average is $153.99 and its two-hundred day moving average is $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.42%. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.